Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 2020-07, Vol.396 (10246), p.255-266
Hauptverfasser: Simpson, Eric L, Sinclair, Rodney, Forman, Seth, Wollenberg, Andreas, Aschoff, Roland, Cork, Michael, Bieber, Thomas, Thyssen, Jacob P, Yosipovitch, Gil, Flohr, Carsten, Magnolo, Nina, Maari, Catherine, Feeney, Claire, Biswas, Pinaki, Tatulych, Svitlana, Valdez, Hernan, Rojo, Ricardo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!